CLAIMS

1. Crystal form A of 3-cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester, which exhibits the following XRPD peaks: 7.93; 10.32; 13.51; 16.18; 20.2; and 24.87±0.2 degrees/2 theta (CuKα2).

2. Crystal form A of 3-cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester according to claim 1, which exhibits the following XRPD peaks: 7.93; 10.32; 12.72; 13.51; 16.18; 17.79; 18.94; 20.2; and 24.87±0.2 degrees/2 theta (CuKα2).

3. Crystal form A of 3-cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester according to claim 1, which exhibits the following XRPD peaks: 7.48; 7.93; 8.55; 10.32; 12.72; 13.51; 16.18; 17.79; 18.94; 20.2; 23.63; 24.87; and 25.82±0.2 degrees/2 theta (CuKα2).

4. Use of the crystal form A of 3-cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester according to any one of claims 1-3 in the manufacture of a medicament for treating an inflammatory or obstructive respiratory disease selected from the group consisting of asthma and chronic obstructive pulmonary disease (COPD).